About Us

Providing positive solutions

Biocosm Inc. is a biomedical research and development (R&D) corporation, established as a spin-off from Technology Holding, LLC, a company that specializes in incubating early stage innovations since 2002.

Biocosm Inc. enjoys financial and strategic, business and product development backing from established partners, and is funded by private investors. In addition to the supporting staff, Biocosm Inc. is managed by a team of highly skilled physician and scientists. Biocosm Inc. combines state-of-the-art biomedical research with innovative engineering technology.

Our Mission

Auto Injectors

Employ a robust and user-friendly auto injector technology to bring injectable therapy to patients at home.

Biological Therapy

Develop novel biological therapy for patients with hematologic and oncologic diseases.

Our Team

The current management team consists of academic, biomedical, and bioengineering researchers



Chief Executive Officer


Mukund Karanjikar, PhD

Chief Operating Officer


Bhavin Vadgama, PhD

Chief Technology Officer


Robert Price, PhD

Chief Regulatory Officer

Team Profile

Dr. Lim has been a leader in hematology and oncology for over 30 years. He is a practicing physician and Professor of Medicine and has held leadership positions at a number of Universities including Brown University, University of Pittsburgh, and New York Medical College. He has been responsible for strategic development of new clinical and research programs focused on translational innovations, bringing new therapies to market. He has run more than 30 clinical trials and worked with many pharma companies in both investigator-initiated studies and pre-licensing studies, and is experienced in regulatory matters such as IND applications. He has received more than $14 million extramural funding from private corporations and the National Institute of Health. He is currently Section Editor for Journal of Translational Medicine. He has more than 150 publications and four patents credited to him. With his wealth of knowledge in administration, healthcare service delivery, research innovation, translational experience, and program development, he co-founded Biocosm, Inc. with Dr. Mukund Karanjikar.
Dr. Karanjikar has more than 15 years of experience in commercialization of new innovations developed internally as well as in licensed from multiple universities and national laboratories. He is credited with more than 20 patents. He has a breadth of experience in stakeholder management, supply chain management, and manufacturing scale up from his time working in Fortune 500 companies as senior scientific staff and as a manager. He has been instrumental in creating spin-off companies based on academic innovations that have raised private capital beyond initial Government funding. He co-founded Biocosm Inc. with Dr. Seah Lim in early 2019.
Dr. Vadgama earned his PhD in Mechanical Engineering and has 15 years of experience in product design and development. He is also heading the operations as the Regional Director for an engineering firm designing and manufacturing ball and roller bearings for critical applications. He has a breadth of expertise at researching and customizing products for a wide variety of clients including medical devices and commercial solutions besides industrial products. With this background, Dr. Vadgama came on board the Biocosm, Inc. team to develop the innovative and patented platform for auto injectors to be used for vital healthcare applications.
Dr. Price earned his PhD in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah. He has 11 years of experience in oncology, infectious disease, inflammation, and medical device development. His work has been funded by the National Institutes of Health, US Department of Defense, US Department of Energy, National Science Foundation, and private corporations. Through this work he has extensive experience working in regulated environments including GLP, cGMP, ITAR controlled, and others.

Research & Development


The first in our pipeline is terbutaline auto injector, aimed at treating patients with exacerbation of asthma and chronic obstructive pulmonary disease. Others in the pipeline include steroids and opioid overdose reversal agents.

Design of a dual-chamber auto injector for combination therapy.


Research is ongoing into novel biologics for therapy of sickle cell disease and as adjuvant to immune checkpoint inhibitor therapy for lung cancer.


A novel peptide-based advanced therapeutic for asthma (funded by the National Institute of Health).

Contact Us

Connecting to The Outside World